Treatment of Androgenetic Alopecia in Females, 9 Beam
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00981461 |
|
Recruitment Status :
Completed
First Posted : September 22, 2009
Results First Posted : July 30, 2012
Last Update Posted : August 10, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Androgenetic Alopecia Hair Loss Female Pattern Baldness | Device: HairMax LaserComb Device: Control Device | Not Applicable |
This is a randomized double-blind, control device clinical study across 5 sites, evaluating changes in terminal hair count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).
The trial with 60 female subjects who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Ludwig I-4, II-1, II-2, or frontal, have active hair loss within the last 12 months.
Subjects will use the device on three non-concurring days a week as directed per device for 26 weeks duration.
Initial efficacy endpoint for each subject will be assess at visit 4 (week 16).
Safety analysis will be assessed based on the reports of adverse events during study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 72 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 9 Beam Model: For the Treatment of Androgenetic Alopecia in Females |
| Study Start Date : | October 2009 |
| Actual Primary Completion Date : | October 2010 |
| Actual Study Completion Date : | October 2010 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: LLT Device 2009 9 Beam
HairMax LaserComb
|
Device: HairMax LaserComb
Device application 3 times week, for 26 weeks |
|
Sham Comparator: control device
control device
|
Device: Control Device
Device application 3 times week, for 26 weeks |
- Changes in Terminal Hair Count Week 16 and 26 Weeks Over Baseline [ Time Frame: Baseline, 16 weeks, 26 weeks ]The primary analysis of effectiveness was an analysis of covariance, which separately modeled terminal hair count at Week 16 and Week 26 as a function of treatment group (HairMax LaserComb 2009 9 Beam vs.control), study center, age (as a continuous variable), and Fitzpatrick Skin Type classification (as a categorical variable with four levels). The active group was compared to the control device using least squares means with a two-sided test at the 5% level of significance.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Diagnosis of androgenetic alopecia
- Fitzpatrick Skin Types I-IV
- Ludwig I-4, II-1, II-2, or frontal
- Active hair loss within last 12 months
Exclusion Criteria:
- Photosensitivity to laser light
- Malignancy in the target area
- Pregnancy
- Lactating females
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00981461
| United States, Florida | |
| Jose Mendez, DO | |
| Miami, Florida, United States, 33144 | |
| Abe Marcadis, MD | |
| Palm Beach, Florida, United States | |
| United States, New Jersey | |
| David Goldberg, MD | |
| Hackensack, New Jersey, United States | |
| United States, New York | |
| Sadick Research Group | |
| New York, New York, United States, 10075 | |
| United States, Virginia | |
| Janet Hickman, MD | |
| Lynchburg, Virginia, United States, 24501 | |
| Principal Investigator: | Michael Jarratt, M.D. | DermaResearch, Inc. | |
| Principal Investigator: | Abe Marcadis, M.D. | Palm Beach Research Center | |
| Principal Investigator: | David Goldberg, M.D. | Hackensack, NJ | |
| Principal Investigator: | Neil S Sadick, MD | Sadick Research Group | |
| Principal Investigator: | Jose Mendez, DO | International Dermatology Research, Inc. | |
| Principal Investigator: | Janet Hickman, MD | The Education and Researvh Foundation |
| Responsible Party: | Lexington International, LLC |
| ClinicalTrials.gov Identifier: | NCT00981461 |
| Other Study ID Numbers: |
151.0805 |
| First Posted: | September 22, 2009 Key Record Dates |
| Results First Posted: | July 30, 2012 |
| Last Update Posted: | August 10, 2012 |
| Last Verified: | August 2012 |
|
Andregenetic Alopecia Hair Loss Female Pattern Baldness |
|
Alopecia Alopecia Areata Hypotrichosis |
Hair Diseases Skin Diseases Pathological Conditions, Anatomical |

